|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011881,
umls-concept:C0020538,
umls-concept:C0030705,
umls-concept:C0034787,
umls-concept:C0070317,
umls-concept:C0087111,
umls-concept:C0162574,
umls-concept:C0229671,
umls-concept:C0288171,
umls-concept:C0332307,
umls-concept:C0441889
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-5-16
|
|
pubmed:abstractText |
The aim of this post-hoc analysis of a prospective study in patients with type 2 diabetic nephropathy was to investigate whether treatment with the angiotensin II type 1 receptor blocker irbesartan leads to a reduction in the serum levels of the advanced glycation end products (AGEs) pentosidine and N(epsilon)-carboxymethyllysine (CML).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amlodipine,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Arginine,
http://linkedlifedata.com/resource/pubmed/chemical/Biphenyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Glycosylation End Products, Advanced,
http://linkedlifedata.com/resource/pubmed/chemical/Lysine,
http://linkedlifedata.com/resource/pubmed/chemical/N(6)-carboxymethyllysine,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/irbesartan,
http://linkedlifedata.com/resource/pubmed/chemical/pentosidine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1660-2110
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2008 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
108
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
c291-7
|
|
pubmed:meshHeading |
pubmed-meshheading:18434751-Aged,
pubmed-meshheading:18434751-Amlodipine,
pubmed-meshheading:18434751-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:18434751-Antihypertensive Agents,
pubmed-meshheading:18434751-Arginine,
pubmed-meshheading:18434751-Biphenyl Compounds,
pubmed-meshheading:18434751-Calcium Channel Blockers,
pubmed-meshheading:18434751-Diabetes Mellitus, Type 2,
pubmed-meshheading:18434751-Diabetic Nephropathies,
pubmed-meshheading:18434751-Double-Blind Method,
pubmed-meshheading:18434751-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:18434751-Female,
pubmed-meshheading:18434751-Follow-Up Studies,
pubmed-meshheading:18434751-Glomerular Filtration Rate,
pubmed-meshheading:18434751-Glycosylation End Products, Advanced,
pubmed-meshheading:18434751-Humans,
pubmed-meshheading:18434751-Hypertension,
pubmed-meshheading:18434751-Linear Models,
pubmed-meshheading:18434751-Lysine,
pubmed-meshheading:18434751-Male,
pubmed-meshheading:18434751-Middle Aged,
pubmed-meshheading:18434751-Statistics, Nonparametric,
pubmed-meshheading:18434751-Tetrazoles
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
|
|
pubmed:affiliation |
Department of Internal Medicine III, University of Jena, Jena, Germany. martin.busch@med.uni-jena.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
